EXPLORER-CN data presented in oral late-breaking science session at ESC 2023 Data from the trial published simultaneously in JAMA Cardiology Mavacamten demonstrated improvement in Valsalva LVOT peak ...
Even though mortality and hospitalization rates have improved, the quality of life for those living with hypertrophic cardiomyopathy (HCM) can be compromised with limiting symptoms such as exertional ...
“The SEQUOIA-HCM trial demonstrated that aficamten can reliably and safely eliminate LVOT obstruction in patients with obstructive HCM using a simple and stepwise dosing regimen, and was associated ...
A second-generation cardiac myosin inhibitor showed promise for the treatment of obstructive hypertrophic cardiomyopathy (HCM) in the phase II REDWOOD-HCM trial. In the dose-finding study, 10 weeks of ...
Bristol Myers Squibb, a global biopharmaceutical company, announced positive topline results from SCOUT-HCM, a phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin ...
Bristol-Myers Squibb Company (NYSE:BMY) is one of the cheap S&P 500 stocks to invest in now. On January 12, Bristol-Myers Squibb announced positive topline results from its Phase 3 SCOUT-HCM clinical ...
Preemptive alcohol septal ablation appears to lower the risk of life-threatening left ventricular outflow tract (LVOT) obstruction in select patients undergoing transcatheter mitral valve replacement ...
Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results